Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 4c; Boosts FY13 Outlook
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.36, $0.04 better than the analyst estimate of $0.32. Revenue for the quarter came in at $133.44 million versus the consensus estimate of $129.43 million.
Myriad Genetics, Inc. sees FY2013 EPS of $1.50-1.55, versus prior guidance of $1.44-1.48 and the consensus of $1.47. Myriad Genetics, Inc. sees FY2013 revenue of $570-585 million, versus prior guidance of $550-565 million and the consensus of $563.5 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Myriad Genetics, Inc. sees FY2013 EPS of $1.50-1.55, versus prior guidance of $1.44-1.48 and the consensus of $1.47. Myriad Genetics, Inc. sees FY2013 revenue of $570-585 million, versus prior guidance of $550-565 million and the consensus of $563.5 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.